Smart Contact Lenses: Where Glucose and Eye Pressure Monitoring Actually Stand

👁️ Two Different Sensing Problems, Two Different Outcomes

Glucose-sensing lenses try to measure glucose concentration in tear fluid and use it as a proxy for blood glucose — a genuinely appealing idea, since it could offer needle-free, continuous monitoring for people with diabetes. The core scientific challenge is whether tear glucose reliably tracks blood glucose closely enough, quickly enough, to be clinically useful.

Eye-pressure (IOP) sensing lenses try to detect changes in intraocular pressure — a key risk factor for glaucoma — by measuring subtle changes in corneal curvature over time, rather than measuring pressure directly. This is a fundamentally different, and so far more tractable, engineering problem, which helps explain why this category has real regulatory clearance while glucose-sensing lenses don’t.

📉 What Happened to the Google Glucose-Sensing Lens

This is worth telling in some detail, because it’s one of the clearest, most well-documented examples in all of health tech of an idea that generated enormous hype and funding, and then honestly failed on the science.

Google announced the glucose-sensing contact lens project in January 2014, describing a prototype with a wireless chip and miniaturized glucose sensor embedded between two layers of soft contact lens material, capable of taking a glucose reading roughly once per second. Later that year, Novartis’s eye-care division Alcon partnered with Google (and later Verily, the Alphabet life-sciences spinoff) to bring the lens to market, with the explicit goal of freeing people with diabetes from routine finger-stick testing.

That matters for evaluating any glucose-sensing lens claim you encounter today. A 2022 peer-reviewed review published in Frontiers in Medicine still described the correlation between tear and blood glucose concentrations as “controversial” — meaning the core scientific question Verily walked away from in 2018 remains genuinely unresolved in the research literature years later. More recent academic work, including a 2020 study in Science Advances demonstrating a combined glucose-sensing and drug-delivery lens tested in live rabbit eyes, and a March 2026 review in Frontiers in Science and Engineering surveying recent tear-glucose sensing research, shows this remains an active, serious area of academic study — but active research is a different thing than a validated product.

✅ What’s Actually FDA-Cleared: The Triggerfish Lens for Glaucoma

The Sensimed Triggerfish contact lens sensor tells a genuinely different story. It received CE certification in Europe in 2008 and FDA clearance in the United States in 2016, through the FDA’s De Novo pathway (decision summary DEN140017). Rather than measuring glucose, it detects changes in corneal curvature believed to correlate with intraocular pressure fluctuations, worn continuously for a 24-hour recording session that’s later reviewed by a healthcare professional.

It’s worth being precise about what this clearance actually covers, because the FDA’s own summary is specific: Triggerfish is described as “an adjunctive tool to tonometry,” with the explicit statement that diagnostic or treatment decisions should rely on traditional tools and methodologies, not on the device alone. It also measures relative changes in eye pressure-related signal, not an absolute intraocular pressure reading in mmHg — a real technical limitation, since it can’t be directly compared to a standard tonometry reading number-for-number.

Triggerfish is real, FDA-cleared, and safe — but it’s a supplementary data-gathering tool used under a clinician’s supervision, not a standalone diagnostic.

The clinical evidence is genuinely mixed, which is worth saying plainly rather than glossing over. A review in Clinical Ophthalmology found the device safe, well-tolerated, and capable of producing reproducible results — real positives. But a separate clinical review noted that correlation with standard tonometer readings has varied considerably across studies, “in some cases revealing good correlation with tonometer values, in others poor or no correlation at all,” and concluded that the interpretation of 24-hour profile data isn’t standardized, with no consistent definition of what counts as a clinically meaningful “fluctuation.” Some sponsor-run clinical trials registered for the device were also terminated or withdrawn — in at least one case explicitly for administrative reasons (staff departures) rather than a safety or efficacy problem, which is a normal, non-alarming reason trials sometimes end, but worth noting for anyone digging into the registry themselves.

⚖️ Why One Worked and the Other Didn’t (So Far)

The contrast between these two lenses is genuinely instructive. Triggerfish doesn’t need to precisely quantify an absolute value — it’s designed to detect a pattern of change over time, and clinicians interpret that pattern relative to a patient’s own baseline. Glucose-sensing lenses, by contrast, need to accurately quantify a specific, clinically actionable number, closely enough to guide real insulin-dosing decisions — a dramatically higher bar for a fluid, tear glucose, that turns out to be a genuinely difficult and inconsistent proxy for blood glucose. That gap in what each technology actually needs to prove is a big part of why one has real FDA clearance today and the other, despite years of major-company investment, does not.

🌐 The Broader “Smart Lens” Landscape

It’s worth knowing that glucose and IOP sensing aren’t the only things “smart contact lens” gets used to describe, which adds to the category confusion. Other well-funded efforts — like Mojo Vision’s augmented- reality display lens — pursued a completely different goal (an in-eye heads-up display, not health monitoring) and have since pivoted away from that original consumer vision entirely, which is its own instructive example of how much harder real-world commercialization is than an impressive lab demo. Market research firms have projected the broader smart contact lens category (spanning health monitoring, AR, and vision-correction applications) growing from roughly $115 million in 2018 to over $1.6 billion by 2026 — a figure worth reading as an industry growth projection across many different sub-technologies, not as evidence that any specific health-monitoring claim within that category is validated or close to market.

📊 Quick Comparison

📋 Questions to Ask About Any “Smart Contact Lens” Claim

• Is this measuring glucose, or eye pressure? These are different technologies with completely different evidence bases — don’t let “smart contact lens” as a category imply they’re equally mature.
• Does this specific product hold FDA clearance, or is it a research prototype or academic study? As of this writing, that distinction alone rules out every glucose-sensing lens and applies only to Triggerfish-style IOP sensors.
• Is it described as a standalone diagnostic, or an adjunctive tool used alongside standard care? Triggerfish’s actual clearance is explicitly the latter.
• If it’s a new glucose-sensing lens claim, does it address the tear-blood correlation problem directly — the exact issue that ended Google and Alcon’s five-year, well-funded effort? A credible claim should engage with that history, not ignore it.
• Who is the manufacturer, and is there a specific published or FDA-reviewed study behind the claim — not just a press release or prototype demo?

🎯 Who This Is Actually Relevant To

If you have diabetes and are curious about non-invasive glucose monitoring, the honest current answer is that a smart contact lens isn’t a realistic option today, regardless of what a headline or startup demo might suggest — established continuous glucose monitors remain the validated, available technology for that need. Our earlier look at what the research actually shows about continuous glucose monitors covers what is genuinely available and evidence-backed in that space right now.

If you or a family member has glaucoma or ocular hypertension, Triggerfish is a real option to discuss with an ophthalmologist specifically for capturing a 24-hour eye pressure fluctuation pattern that a single in-office reading would miss — with the clear understanding, based on its own FDA clearance terms, that it supplements rather than replaces standard tonometry and clinical judgment.

❓ Frequently Asked Questions

Can I buy a contact lens that monitors my blood sugar?

No. No glucose-sensing contact lens currently holds FDA clearance for continuous glucose monitoring in humans. Google and Alcon’s well-funded five-year attempt at this was shelved in 2018 due to an unresolved scientific limitation, and that core problem remains an active, unsolved area of academic research as of recent published reviews.

Is the Triggerfish contact lens for glaucoma actually approved?

Yes — it received FDA clearance in 2016 through the De Novo pathway, and CE marking in Europe in 2008. However, it’s cleared specifically as an adjunctive tool used alongside standard tonometry, not as a standalone diagnostic device, and it measures relative pressure-related changes rather than an absolute eye pressure value.

Why did Google’s smart contact lens project fail?

According to Verily’s own 2018 announcement, the project’s clinical work found insufficient, inconsistent correlation between glucose levels in tear fluid and glucose levels in blood — a fundamental measurement challenge in the complex on-eye environment, not a business or funding decision.

Are there any new glucose-sensing contact lenses in development?

Yes, active academic research continues, including tear-glucose sensor studies published as recently as 2026. But this remains preclinical, laboratory-stage research (including animal studies), not a product with regulatory clearance or available clinical validation in humans.

📚 Sources & References

• STAT News, “After five years, Verily shelves project to create glucose-sensing contact lens”
• CNBC, “Alphabet’s Verily stops ‘smart lens’ program to measure glucose levels in tears”
• Eyewire+, “Verily, Alcon, Halt Project to Create a Glucose-Measuring Contact Lens”
• Elsherif, M., Moreddu, R., Alam, F., et al., “Wearable Smart Contact Lenses for Continual Glucose Monitoring: A Review,” Frontiers in Medicine, 2022
• Yu, Y., et al., “Wireless smart contact lens for diabetic diagnosis and therapy,” Science Advances, 2020
• “Advances in Smart Contact Lenses for Tear Glucose Monitoring: A Review,” Frontiers in Science and Engineering, 2026
• Registrar Corp, “FDA Compliance for Smart Contact Lenses” (device classification and regulatory pathway)
• U.S. Food and Drug Administration, De Novo Summary DEN140017 — SENSIMED Triggerfish
• touchOPHTHALMOLOGY, “Contact Lens Sensor Triggerfish – What Do We Know?”
• Dovepress/Taylor & Francis, “The Sensimed Triggerfish contact lens sensor: efficacy, safety, and patient perspectives,” Clinical Ophthalmology, 2017
• ClinicalTrials.gov, NCT01028664, NCT01253109, NCT01495299 — Sensimed Triggerfish clinical trial registrations

Verification notes: The Verily/Google/Alcon glucose lens discontinuation is corroborated across multiple independent contemporaneous sources (STAT News, CNBC, Eyewire+) and Verily’s own public statement, and is treated as well-established fact. Sensimed Triggerfish’s FDA clearance was verified directly against the FDA’s own De Novo summary document; its “adjunctive tool” limitation and the mixed correlation findings across studies are drawn from independent peer-reviewed clinical reviews rather than manufacturer materials. Claims about newer academic glucose-lens research (Science Advances, Frontiers in Science and Engineering) are presented explicitly as preclinical/laboratory-stage research, not as evidence of an available or FDA-reviewed product.

💡 The Bottom Line

“Smart contact lens” is a category name that hides two very different stories. Glucose-sensing lenses represent one of health tech’s most instructive failures: a scientifically serious, well-funded, multi-year effort that ran directly into a hard biological limitation and was honestly shelved rather than pushed to market before it was ready — a contrast worth remembering the next time a glucose-lens headline promises otherwise. Eye-pressure sensing lenses, by contrast, cleared a real (if narrower and more modest) bar: FDA authorization as an adjunctive 24-hour monitoring tool, with genuine but still-evolving clinical evidence behind it. Neither story is really about hype versus science — they’re both about how difficult it is to turn a compelling engineering idea into something a regulator and the clinical evidence can actually stand behind, and why that process sometimes takes longer, or ends differently, than the initial announcement promised.